Clinical Trials List
2019-01-08 - 2020-09-30
Phase I
Not yet recruiting3
ICD-9140.0
Malignant neoplasm of upper lip, vermilion border
-
Trial Applicant
AbbVie
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/06/01
Investigators and Locations
Co-Principal Investigator
- 廖斌志 Division of Hematology & Oncology
- JIN-YUAN SHIH Division of General Internal Medicine
- 蔡子修 Division of General Internal Medicine
- 張端瑩 Division of Hematology & Oncology
- Jih-Hsiang Lee Division of Hematology & Oncology
- CHAO-CHI HO CHAO-CHI HO Division of General Internal Medicine
- 楊景堯 Division of General Internal Medicine
- Wei-Wu Chen Division of Hematology & Oncology
- James Chih-Hsin Yang Division of Hematology & Oncology
- Chong-Jen Yu Division of General Internal Medicine
- 許嘉林 Division of General Internal Medicine
- 林季宏 Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- 徐偉勛 Division of Hematology & Oncology
- 廖唯昱 Division of Hematology & Oncology
- YEN-SHEN LU Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Audit
None
Co-Principal Investigator
- Wen-Pin Su Division of General Internal Medicine
- Jui-Hung Tsai Division of General Internal Medicine
- Yu-Min Yeh Division of General Internal Medicine
- Chia-Jui Yen Division of General Internal Medicine
- Chien-Chung Lin
- Wei-Pang Chung Division of General Internal Medicine
- Shang-Yin Wu Division of General Internal Medicine
- Po-Lan Su
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Audit
None
Co-Principal Investigator
- Su-Peng Yeh 未分科
- Li-Yuan Bai 未分科
- Chi-Ching Chen 無
- Ching-Chan Lin 無
- Yu-Min Liao 未分科
- Ching Yun Hsieh 未分科
- Yao-Chung Wu 無
- Ming-Hung Tsai 未分科
- Chen-Yuan Lin 未分科
- Tzu-Ting Chen 無
- Ming-Yu Lien 無
- Che-Hung Lin 未分科
- Liang-Chih Liu 無
- Chih-Yen Tu 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
5 participants
-
Global
125 participants